Bicycle Therapeutics Announces Strategic Reprioritization, Pipeline Progress, and Q4/FY2025 Financial Results

Key Highlights and Shareholder-Impacting Developments

• Strategic Pipeline Reprioritization: Company is shifting focus to BT5528 and next-generation Bicycle® conjugates, including radioconjugates, with major changes to pipeline and workforce.
• Duravelo-2 Zelenectide Update: Phase 2/3 pivotal trial in metastatic urothelial cancer (mUC) identified 6mg/m² as optimal, showing competitive response rates and differentiated safety. However, zelenectide is now deprioritized for internal development; trial is converted to randomized Phase 2.
• Workforce Reduction: 30% workforce cut proposed, with expected operational expense reduction of ~50%, extending cash runway into 2030.
• Strategic Radioisotope Supply Partnerships: Multiple long-term agreements secured to ensure sustainable supply for radiopharmaceutical pipeline, supporting end-to-end development and commercialization of BRCs.
• Solid Capital Position: \$628 million in cash and equivalents as of December 31, 2025, despite increased R&D spend.
• Leadership Changes: Key additions and promotions to strengthen management team during transition.

In-Depth Report

1. Zelenectide Pevedotin (Zelenectide) in mUC: Promising Results, Strategic Deprioritization

The company has completed the dose selection phase of the pivotal Duravelo-2 trial, confirming the 6mg/m² “two weeks on, one week off” regimen as optimal. This arm demonstrated an impressive physician-assessed overall response rate (ORR) of 65% and a blinded independent central review (BICR) confirmed ORR of 58% at a 27-week cutoff, with an additional response observed thereafter, raising ORR to 62%. Importantly, only one patient discontinued due to treatment-related adverse events, highlighting a differentiated safety profile compared to existing standards of care.

Despite these results, regulatory feedback indicated the current study design is no longer an acceptable path for approval. Multiple regulatory pathways exist, but Bicycle Therapeutics is deprioritizing zelenectide for internal development and converting the trial to a randomized Phase 2 study. Future decisions will be informed by data from this study. The company is also discontinuing Duravelo-3 (NECTIN4-amplified breast cancer) and Duravelo-4 (NECTIN4-amplified non-small cell lung cancer). Existing patients will complete treatment, but no new patients will be enrolled.

2. Strategic Reprioritization and Workforce Reduction

Bicycle Therapeutics is embarking on a strategic reprioritization to focus resources on its most promising assets, notably BT5528 (now named nuzefatide pevedotin) and next-generation radioconjugates. This includes a proposed reduction of approximately 30% of its workforce, expected to halve annual operating expenses and extend the company’s cash runway by nearly two years, into 2030. Savings are expected to be significant, with annual operating expenses reduced by about 50% based on current plans.

3. Major Strategic Partnerships for Radiopharmaceuticals Pipeline

Bicycle has secured a 15-year contract (with renewal options) with the UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium, providing a sustainable supply of 212Pb. Collaboration with the UK National Nuclear Laboratory allows for extraction and processing of 228Th and subsequent development of bespoke 212Pb generators by SpectronRx. This unique supply chain enables an isotope-agnostic strategy, supporting the discovery, development, and commercial supply of BRCs. Agreements with Eckert & Ziegler further broaden supply options for radioisotopes.

4. Pipeline Updates and Upcoming Catalysts

• BT5528 (Nuzefatide Pevedotin): Announced as International Nonproprietary Name. Phase 1 combination data (with nivolumab) in mUC and details of new Phase 2 in recurrent pancreatic ductal adenocarcinoma (PDAC) to be presented in H1 2026.
• Bicycle Radioligand Pipeline (BRCs and BIAs): First company-sponsored clinical trial for BT1702 (MT1-MMP targeting BRC) expected to begin in 2027; additional EphA2 human imaging data in H1 2026.
• BT7480 (Bicycle TICA®): Combination data with nivolumab in Nectin-4 expressing tumors to be presented in H1 2026; company will seek partners for further development post-data release.
• Preclinical and Early Clinical Data: New data on MT1-MMP targeting BIA presented at EANM 2025; additional positive preclinical radiotheranostic data support MT1-MMP as a novel cancer target.

5. Leadership Team Evolution

The company has bolstered its leadership: Jennifer Perry, Pharm.D., joins as COO; Alistair Milnes as Chief Corporate Development Officer; Travis Thompson promoted to CFO; Michael Method, M.D., to Chief Medical Officer; and Michael Skynner, Ph.D., as Chief Scientific Officer. These moves are intended to support the pipeline transition and future growth.

6. Financial Results: Q4 and Full Year 2025

• Cash & Equivalents: \$628.1 million (Dec 31, 2025), down from \$879.5 million (Dec 31, 2024), mainly due to increased R&D outlays.
• Revenue: Collaboration revenue of \$48.0 million for Q4 and \$72.6 million for FY2025, up significantly from prior periods due to revenue recognized on Novartis and Bayer collaboration terminations.
• R&D Expenses: \$51.8 million in Q4 and \$240.3 million for FY2025 (up from \$49.8M and \$173.0M in 2024), primarily due to increased zelenectide development, higher personnel costs (including severance), and lower UK R&D tax credits.
• G&A Expenses: \$20.9 million in Q4 and \$79.4 million for FY2025 (slight increase YoY).
• Net Loss: \$20.2 million for Q4 and \$219.0 million for FY2025 (vs \$51.9M and \$169.0M loss in prior year).

Shareholder-Relevant, Price-Sensitive Takeaways

• The deprioritization of zelenectide, despite robust data, marks a significant shift in the company’s risk profile and focus, and may impact market perception of near-term oncology catalysts.
• The substantial workforce reduction and pipeline narrowing are expected to materially extend the company’s cash runway and reduce burn, which may be viewed as positive from a financial stability perspective.
• The strategic repositioning towards next-generation radioconjugates and partnerships to secure raw material supply provide longer-term growth potential, but may increase investor focus on execution risk and pipeline readouts.
• Recent leadership changes position the company for its next phase but will require successful integration and execution to realize value.
• Upcoming catalysts in 2026 (BT5528/nuzefatide and BT7480 data, radioligand program updates) remain potentially significant share price movers.

Conclusion

Bicycle Therapeutics’ Q4 and FY2025 update delivers several price-sensitive developments: a major strategic refocus, the deprioritization of a late-stage asset, significant cost-saving measures, new supply chain partnerships, and near-term pipeline catalysts. Investors should monitor execution of these initiatives and forthcoming data releases, which are likely to drive future share performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties as detailed in official company filings.

View BICYCLE THERAPEUTICS PLC Historical chart here